TOKYO —

Mount Sinai researchers have unveiled groundbreaking insights into how the strongest genetic risk factor for Alzheimer’s disease, APOE4, contributes to devastating brain damage. Two pivotal studies, published in the esteemed journals Cell and Cell Stem Cell, reveal that APOE4 not only inflicts damage upon the brain’s intricate vascular network but also actively promotes the accumulation of toxic proteins characteristic of neurodegenerative conditions. These findings offer a beacon of hope, suggesting that the underlying disease processes may be reversible. Furthermore, the research introduces a revolutionary human brain tissue platform derived from stem cells, poised to significantly accelerate the development of much-needed treatments.

The Insidious Impact of APOE4 on Brain Vasculature

Alzheimer’s disease, a relentless neurodegenerative disorder, progressively erodes memory, cognitive abilities, and behavioral functions, affecting over 7 million older adults in the United States alone. For years, the scientific community has observed a marked deterioration of brain blood vessels as Alzheimer’s progresses, particularly in individuals carrying the APOE4 gene. However, the precise mechanisms driving this vascular decline and its direct contribution to the disease pathology have remained elusive. This uncertainty has often led to the treatment of vascular damage as a mere consequence of Alzheimer’s, rather than a potential driver of the disease itself.

The first study, published in Cell on September 24th, marks a significant stride in demystifying this complex relationship. Mount Sinai scientists meticulously integrated existing datasets to construct a comprehensive single-cell transcriptomic atlas of the human brain’s blood vessels. This unprecedented map provides a granular view of gene activity within the diverse cell types that comprise and support the brain’s vascular system, offering researchers an unparalleled tool to scrutinize the influence of APOE4 on vascular degeneration.

Pericyte Transformation: A Key to Vascular Fibrosis

Through their detailed analysis, the research team identified a critical alteration in the behavior of pericytes – cells that normally play a vital role in stabilizing small blood vessels and maintaining the integrity of the blood-brain barrier. In the presence of APOE4, these crucial support cells undergo a profound transformation, shifting into myofibroblast-like cells. These altered cells then embark on the production of scar tissue, a process known as fibrosis.

This APOE4-induced pericyte transformation directly promotes vascular fibrosis, leading to an increased deposition of amyloid, a hallmark abnormal protein, around the brain’s blood vessels. Such amyloid accumulation can severely impede blood flow, creating a hostile environment that fosters neurodegeneration. This discovery fundamentally reframes our understanding of Alzheimer’s pathology, suggesting that vascular dysfunction driven by APOE4 is not a passive bystander but an active participant in disease progression.

A Glimmer of Reversibility: Targeting TGF-β Signaling

Perhaps the most encouraging aspect of this Cell study is the evidence pointing towards the potential reversibility of this detrimental process. The researchers demonstrated that by inhibiting TGF-β signaling – a key cellular communication pathway involved in tissue remodeling – they could restore pericyte coverage. This intervention also led to a significant reduction in vascular fibrosis and the surrounding amyloid buildup. Crucially, these promising results were replicated in aged APOE4 mice, providing strong preclinical evidence that the vascular degeneration associated with APOE4 is therapeutically targetable.

"Damage to the brain’s blood vessels is not simply a late consequence of Alzheimer’s disease; it is a biologically active process caused by APOE4 that may be reversible," stated Dr. Joel W. Blanchard, Associate Professor of Neuroscience and Stem Cell Biology and Regenerative Medicine at the Icahn School of Medicine at Mount Sinai, and the study’s corresponding author. "These findings reveal new therapeutic targets for preserving vascular function and limiting amyloid accumulation."

Braxton R. Schuldt, an MD/PhD candidate in Neuroscience and researcher in Dr. Blanchard’s laboratory, elaborated on the significance of their findings: "We show that APOE4 converts blood-vessel support cells into scar-producing cells, causing amyloid or abnormal protein buildup to accumulate around the brain’s vessels. Through our experiments, we were able to block this protein buildup process, revealing possible new therapeutic treatment options and strategies for protecting the brain’s circulation in people at high genetic risk for Alzheimer’s disease."

The Power of miBrains: Unlocking Human Brain Disease Mechanisms

A cornerstone of this groundbreaking research is the development and utilization of "miBrains" – sophisticated three-dimensional human brain tissue models engineered by the Mount Sinai team from induced pluripotent stem cells. These miBrains faithfully replicate key features of human brain tissue, including its complex network of blood vessels, providing an unparalleled platform for studying human-specific disease mechanisms.

The Blanchard laboratory masterfully integrated findings derived from miBrains with data from preclinical models, postmortem human brain tissue, and transcriptomic analyses. This multi-pronged approach allowed for robust confirmation and expansion of observations, building a comprehensive picture of disease progression. By converging these diverse systems, the scientists were able to meticulously reconstruct events that precede the severe vascular abnormalities observed in postmortem human brain samples. This enabled them to pinpoint the underlying molecular mechanisms and rapidly test potential therapeutic interventions.

APOE4’s Dual Threat: Disrupting Protein Clearance Pathways

Complementing the vascular insights, the second study, published in Cell Stem Cell, delves into another critical role of APOE4: its influence on the accumulation of abnormal proteins within the brain. Protein aggregation is a defining characteristic of devastating neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease. However, investigating the precise cellular processes that lead to the formation of these toxic deposits within a living human brain has historically been exceptionally challenging. The miBrain system, with its ability to model complex human brain-like tissue under controlled laboratory conditions, offers a revolutionary solution to this long-standing hurdle.

The miBrains used in this study encompass all major cell types found in the human brain, including neurons, supporting glial cells, myelin-producing cells, and the cells that form blood vessels. In a striking parallel to human disease, miBrains engineered to carry the APOE4 gene exhibited significantly higher levels of abnormal alpha-synuclein. This protein is most strongly implicated in Lewy body dementia and Parkinson’s disease, underscoring the broad implications of these findings for multiple neurodegenerative disorders. Despite its clinical significance, the precise cellular pathways driving alpha-synuclein accumulation have remained poorly understood.

Cholesterol Accumulation: A Bottleneck in Cellular Waste Removal

Through their meticulous experiments with miBrains, the researchers uncovered a critical link between APOE4, cholesterol metabolism, and protein clearance. They discovered that APOE4 triggers the accumulation of cholesterol within astrocytes – essential support cells that perform numerous vital functions in maintaining brain health. This surplus cholesterol acts as a disruptive agent, impairing the astrocytes’ lysosomal waste-disposal system. Consequently, the cells become less efficient at breaking down and clearing alpha-synuclein. Instead of being eliminated, the protein accumulates and subsequently spreads to neurons, where it contributes to the formation of harmful, toxic deposits.

These revelations suggest that dysregulation of cholesterol metabolism within astrocytes, coupled with impaired lysosomal function, represents a promising new avenue for therapeutic intervention in both Alzheimer’s and Parkinson’s diseases. The miBrain platform’s ability to trace this cascade of events – from APOE4’s influence on lipid buildup in astrocytes to diminished alpha-synuclein clearance and the subsequent formation of toxic protein aggregates – provides a powerful framework for understanding and targeting these complex cellular processes. The findings unequivocally point towards both lipid metabolism and cellular waste removal systems as critical targets for future neurodegenerative disease therapies.

The Future of Personalized Medicine: Cryopreserved miBrains

Beyond their immediate scientific discoveries, the miBrain system offers a significant advantage for the future of drug development and personalized medicine. These advanced tissue models can be cryopreserved, allowing for their storage and future use in experiments.

"A key advance of our technology is that miBrains with predefined cellular compositions and disease-related factors can be cryopreserved," explained Dr. Louise Mesentier-Louro, Assistant Professor of Neuroscience and Stem Cell Biology and Regenerative Medicine at the Icahn School of Medicine at Mount Sinai, and lead author of the Cell Stem Cell study. "This capability improves reproducibility and scalability of complex disease modeling and supports more efficient drug development and validation."

Looking ahead, Mount Sinai researchers are actively developing miBrains derived from individual patients. This pioneering approach holds the potential to revolutionize our understanding of how neurodegenerative diseases manifest uniquely in each person and how they might respond to specific therapeutic interventions.

"At Mount Sinai, we are creating and cryopreserving miBrains from patients," Dr. Blanchard further emphasized. "This will enable personalized studies into how neurodegenerative disease develops and how individuals may respond to therapies. By enabling potential therapies to be tested earlier and more efficiently, the miBrain platform could help bridge the gap between laboratory discoveries and treatments for a broad range of disorders."

Funding and Broader Implications

The impactful research presented in these two studies was made possible through substantial support from various national and private organizations. The Cell study examining vascular degeneration received funding from the National Aeronautics and Space Administration (NASA) and the National Institute on Aging (NIA) at the National Institutes of Health (NIH), along with contributions from The SWT Foundation and the CureAlz Fund. The Cell Stem Cell study focusing on abnormal protein buildup was supported by NASA, Aligning Science Across Parkinson’s (ASAP) through the Michael J. Fox Foundation for Parkinson’s Research, the National Institute of Neurological Disorders and Stroke (NINDS) and the NIA at the NIH, the CureAlz Fund, and The SWT Foundation.

The implications of these findings are profound. By elucidating the intricate ways APOE4 drives both vascular damage and protein aggregation, and by demonstrating the potential for therapeutic reversal, this research opens new frontiers in the fight against Alzheimer’s disease and potentially other neurodegenerative conditions. The development of the miBrain platform represents a paradigm shift in how these complex diseases are modeled and studied, accelerating the translation of fundamental scientific discoveries into tangible treatments for patients. The promise of personalized therapeutic testing, enabled by patient-derived miBrains, signals a new era where treatments can be tailored to individual genetic profiles and disease manifestations, offering unprecedented hope for millions affected by these debilitating conditions.